Journal of Neuro-Oncology

, Volume 82, Issue 2, pp 207–209

A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma

Clinical–Patient Studies

DOI: 10.1007/s11060-006-9269-z

Cite this article as:
Chamberlain, M.C. & Chalmers, L. J Neurooncol (2007) 82: 207. doi:10.1007/s11060-006-9269-z


There is no standard of care for elderly patients (age ≥ 70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4–14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.


Elderly patients Glioblastoma Dose-dense temozolomide Deferred radiotherapy 

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  1. 1.Department of Interdisciplinary OncologyMoffitt Cancer Center and Research InstituteTampaUSA